Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

Cisplatin 7Cetuximab 6Radiotherapy, Intensity-Modulated 4pembrolizumab 3durvalumab 3Radiotherapy 2Radiation 2Observation 2Drug Therapy 2Celecoxib 2Bupropion 2130-nm albumin-bound paclitaxel 2trametinib 1sodium thiosulfate 1gluconic acid 1ficlatuzumab 1Zinc 1Watchful Waiting 1Varenicline 1Transcutaneous Electric Nerve Stimulation 1Tobacco Use Cessation Devices 1Tadalafil 1Sirolimus 1RRx-001 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Pilocarpine 1Photochemotherapy 1Periodontal Debridement 1Oral Hygiene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Mouth Neoplasms × (225)Ac-DOTA-c(RGDyK) × Clear all
NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡